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Abstract
Background: There is no confirmed strategy for treating painful bladder syndrome/interstitial cystitis (PBS/IC) with
unclear etiology. Therefore, a pilot study was carried out to evaluate the efficacy and safety of hyperbaric oxygen
(HBO) therapy in treatment-resistant PBS/IC patients.
Methods: HBO treatment (2.0 ATA for 60 minutes/day × 5 days/week for 2 or 4 weeks) was performed on 11
patients with severe symptoms that had not been improved by previous therapy regimens between December
2004 and July 2009.
Results: Seven of the 11 patients demonstrated persistent improvement in symptoms during the 12 months after HBO
treatment. These responders demonstrated a decrease in the pelvic pain scale and urgency scale from 7.7 ± 1.0 and,
6.6 ± 0.9 to 3.4 ± 2.5 and 4.3 ± 2.4 after 12 months, respectively (p < 0.05). The total score of the interstitial cystitis
symptom index and 24-hour urinary frequency demonstrated a significant sustained decrease from the baseline. Two
responders, who received an additional course of HBO 12 and 13 months after initial treatment, respectively, did not
suffer impairment for more than two years. There was one case of transient eustachian tube dysfunction and three
cases of reversible exudative otitis media as a consequence of HBO treatment.
Conclusions: HBO is a potent treatment for PBS/IC patients resistant to conventional therapy. It was well tolerated
and provided maintained amelioration of pain, urgency and urinary frequency for at least 12 months.
Background
Painful bladder syndrome/interstitial cystitis (PBS/IC) is a
collective term covering a range of clinical complaints and
pathological findings. Approximately 10-50% of PBS/IC
patients demonstrate a classical mucosal ulcer (Hunner’s
ulcer), and the majority are diagnosed on the basis of posi-
tive factors and exclusions derived from the diagnostic cri-
teria of the National Institute of Diabetes and Digestive
and Kidney Diseases for IC [1,2]. The etiology of PBS/IC
includes a diversity of factors and remains poorly under-
stood. Therefore, appropriate therapy has not been estab-
lished from clinical evidence [3-5]. Hyperbaric oxygen
(HBO) therapy has been reported to be effective in
patients with cyclophosphamide-induced hemorrhagic
cystitis and chronic radiation cystitis for approximately
20 years [6-9]. The pathological finding of chronic radia-
tion cystitis is similar to PBS/IC, focusing on ischemia and
a reduction in bladder capacity due to fibrosis of the blad-
der wall [10-12]. On the basis of these findings, a pilot
study concerning HBO treatment in several PBS/IC
patients whose symptoms had not been improved by other
conventional treatments was carried out.
Methods
From December 2004 to July 2009, 11 PBS/IC patients
whose symptoms were resistant to conventional therapy
were treated with HBO therapy. All patients had
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cation, intrasvesical instillation of heparin and hydrodis-
tension. The ethical review board of our institute
approved the study, and informed consent was obtained
from all patients. Patients were treated with HBO (2.0
ATA for 60 minutes/day × 5 days/week for two or four
weeks) sequentially after previous hydrodistention. After
10 sessions had been performed, patients were assessed
and 10 more sessions were performed in some cases;
eight patients underwent 10 sessions and three received
20 sessions (Table 1). In the case of patients with severe
urgency or incontinence, pads were worn during treat-
ment sessions. The efficacy of HBO treatment for PBS/
IC disease was assessed using the score of O’Leary-Sant
IC symptom and problem index (ICSI), comprising eight
questions with the ranges of 0-5 and 0-4 with regards to
pain and voiding symptoms, respectively, the scales of
pelvic pain and urgency using a visual analogue scale
(VAS) with the range 0-9, bladder capacity, daily voiding
frequency, and endoscopic findings. A responder was
defined as a patient with an improvement in ≥ 1 fraction
among the total score of ICSI, and the scale of pain or
urgency on VAS. The population of two related samples
could not be assumed to be normally distributed. There-
fore, statistical comparisons were performed using the
Wilcoxon signed-rank test for changes from the baseline
in the aforementioned parameters. P < 0.05 was consid-
ered to denote a statistically significant difference.
Results
The patients comprised 10 females and one male; the
mean age was 60.0 years (range 28-79 years). The PBS/
IC diseases in these 11 patients included eight cases of
ulcerative type and three of non-ulcerative type, accord-
ing to intravesical endoscopic findings (Table 1).
Patients were followed up for a median period of
14 months (range 3-50 months) after HBO therapy.
Seven of the 11 patients were classed as responders.
Four patients, who demonstrated no remission or short-
term improvement, were considered non-responders.
Three of four non-responders had non-ulcerative endo-
scopic findings (Table 1). At the end of the HBO
sessions, seven responders demonstrated a significant
improvement in symptoms compared to the pre-treat-
ment baseline (p < 0.05), and had sustained amelioration
with mild impairment during the following 12 months
(Figure 1). After 12 months, the scales concerning pelvic
pain and urgency were still decreased from 7.7 ± 1.0
and 6.6 ± 0.9 to 3.4 ± 2.5 and 4.3 ± 2.4, respectively
(p < 0.05). The total score of ICSI decreased from
26.7 ± 7.0 to 18.7 ± 7.4 (p < 0.05), and the 24-hour
voiding frequency decreased from 22.4 ± 4.0 to 14.6 ±
2.0 (p < 0.05). Two patients (cases one and two) in the
responder group, who had received 20 sessions at the
time of the initial report, underwent 10 secondary ses-
sions of HBO treatment 13 and 14 months after initial
HBO therapy, respectively. The symptoms in these
patients remained stable for more than two years. In
addition, cystoscopic examination demonstrated
marked granulation of the ulcerative lesion (Figure 2)
at the end of HBO treatment in all responders. With
regards to adverse events, there was transient eusta-
chian tube dysfunction in one case and reversible exu-
dative otitis media in three cases. However, no patients
discontinued HBO treatment because of these side
effects.
Table 1 Characteristics of HBO-treated patients and outcome of HBO
Patient Sex Age
(years)
Symptom
duration
(years)
Bladder
capacity on
FVC (ml)
Times of
hydrodistension
before HBO
Sessions of
HBO
treatment
Response
to HBO
PBS/IC subtype
based on
hydrodistension
Observation
duration after
HBO (months)
1* female 79 2.2 40 2 20 Responder Ulcerative 50
2* female 61 4.5 60 2 20 Responder Ulcerative 44
3 female 28 1.8 80 1 10 Non-
responder
Non-ulcerative 4
4 female 68 2.4 70 4 10 Responder Ulcerative 33
5 female 57 3.6 80 4 10 Responder Ulcerative 15
6 male 65 4 50 2 20 Non-
responder
Non-ulcerative 30
7 female 70 3.2 100 1 10 Responder Ulcerative 14
8 female 50 2.1 90 2 10 Non-
responder
Non-ulcerative 4
9 female 70 6.4 40 6 10 Responder Ulcerative 13
10 female 43 3.5 120 1 10 Non-
responder
Ulcerative 3
11 female 70 3.2 50 4 10 Responder Ulcerative 12
*Two patients of case 1, 2 underwent additional 10 sessions after 13, 14 months, respectively.
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Page 2 of 5Figure 1 Changes in evaluated parameters (the total score of ICSI, the scale of pain and urgency on VAS, 24-hour voiding frequency
and maximum bladder volume) from the baseline in seven responders after three, six, nine, and 12 months follow-up after HBO
treatment. The bottom and top of the box are the lower and upper quartiles, respectively, and the ends of whiskers represent the minima and
maxima of the samples.
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The mechanism of action underlying HBO treatment is
attributed to hyper-saturation of the plasma with dis-
solved oxygen. This gives rise to an increased concentra-
tion gradient between the circulation and surrounding
tissues, allowing oxygen to enter damaged hypoxic
urothelial tissues. HBO treatment accelerates growth of
healthy granulation in injured tissues via stimulation of
leukocytic functions including phagocytosis and produc-
tion of growth factors related to angiogenesis [13,14].
HBO therapy has been used predominantly for chronic
radiation cystitis and cyclophosphamide-induced hemor-
rhage cystitis in the last 20 years [6-9]. Chronic radia-
tion cystitis is characterized by various histological
alterations including sub-mucosal hemorrhage, intersti-
tial fibrosis and smooth muscle fibrosis [10], which cor-
respond to classical PBS/IC with ulcerative lesions
[11,15]. Therefore, it was hypothesized that HBO could
be an effective treatment for PBS/IC with typical histo-
logical changes (glomerulations, Hunner’su l c e ra n d
interstitial fibrosis). Seven of 11 cases treated with HBO
demonstrated a significant decrease in urinary frequency
and pelvic pain and an increase in bladder capacity.
Cystoscopic examination revealed the scarring or heal-
ing phase of ulcerative lesions in all responders. Further-
more, the positive effects on symptoms were sustained
for a minimum of 12 months. Van Ophoven et al.c a r -
ried out a pilot study concerning HBO in six PBS/IC
patients [16]. Our group reported that HBO treatment
resulted in a marked improvement of severe PBS/IC
symptoms in the initial two cases [17]. In addition, van
Ophoven’s research group reported the effectiveness of
HBO for PBS/IC on the basis of a randomized, double-
blind, sham controlled clinical study [18]. This study
revealed that the scale of pelvic pain in the HBO treat-
ment group was significantly better than in the sham
control group, and the amelioration in responders was
sustained 12 months after HBO treatment. The results
of our study are almost compatible with their report.
Interestingly, secondary HBO treatment prolonged the
period of remission in two cases (cases 1, 2). Therefore,
it is likely that a repeated course of HBO could acceler-
ate the healing phase of ulcerative PBS/IC disease.
Three of the four cases that responded poorly to HBO
presented with non-ulcerative PBS/IC. Thus, we specu-
late that ulcerative lesion with the most evident expres-
sion of bladder ischemia may be a predictive factor to
result in good response to HBO. HBO therapy was well
tolerated by patients; adverse events including visual dis-
turbance, eustachian tube dysfunction and claustropho-
b i aw e r eu n u s u a l[ 1 9 ] .F u r t h ermore, the advantage of
HBO treatment over conventional therapies such as
hydrodistension [15], intravesical instillation of
dimethyl-sulfoxide (DMSO) [20] and intravesical sub-
mucosal injection of Botulinum toxin type A [21,22] is
that it is non-invasive.
Conclusions
The long-term efficacy of HBO treatment in 11 PBS/IC
patients resistant to other conservative therapies was
investigated. Seven of 11 patients, who underwent 10 or
20 sessions of HBO treatment, demonstrated good
Figure 2 Granulation of an ulcer in the bladder mucosa of an HBO-responder; the arrows indicate the lesions.
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Page 4 of 5amelioration of the evaluated parameters including IC
symptom score, scale for pain and urgency, 24-hour
urinary frequency and bladder volume, for at least one
year. Furthermore, two responders with worsening
symptoms experienced prolonged improvement after
additional HBO treatment sessions. HBO therapy was
well tolerated, with few patients developing transient
eustachian tube dysfunction and reversible exudative oti-
tis media.
T h ep r e s e n ts t u d ys u g g e s t st h a tH B Oc o u l db eu s e d
for the treatment of PBS/IC patients resistant to various
conventional therapies.
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